Project Inform
   

Strategies for first line HIV therapy

May 2008     View PDF     En español

The best starting combination

What is the best combination for people starting therapy?
The question of what combination of HIV drugs a person should use as first line therapy can appear confusing. However, there are a few factors to consider which narrow the range of choices for first line therapy. They include:

  • its potency;
  • its ease of use: how many pills and how often; and
  • its potential for short- and long-term side effects.

The Guidelines list the following combinations as “preferred” first line regimens. This is because research shows that they are potent, well tolerated and easy to take. They also list alternatives that have less data to support their use as first line treatment, but may work just as well.

Federal recommendations for first line therapy
(updated january 2008)

CLASS

PREFERRED

ALTERNATIVE

NOT RECOMMENDED

NRTIs

Truvada
Epzicom

Combivir
ddI + 3TC or FTC

d4T

NNRTI

Sustiva

Viramune

Rescriptor
Intelence

Protease
Inhibitor

Reyataz—boosted
Lexiva—boosted (2x/day)
Kaletra (2x/day)

Reyataz—unboosted
Lexiva—unboosted
Lexiva—boosted, 1x/day
Kaletra 1x/day
Invirase—boosted

Invirase—unboosted
Viracept
Aptivus
Prezista—boosted

 
     
 

© 2008 Project Inform  1375 Mission Street,  San Francisco, CA 94103  415-558-8669
National HIV/AIDS Treatment Hotline 1-800-822-7422 (415-558-9051 local/int'l) 10a-4p Mon-Fri PST